Veena Somasundaram
Laboratory of Cancer Immunometabolism, National Cancer Institute, Frederick, MD
Peter Soukas
Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, Rockville, MD
Jenish Patel
Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, Rockville, MD
Steven Ferguson
Office of Technology Transfer, National Institutes of Health, Rockville, MD.

DOI:https://doi.org/10.5912/jcb1006


Abstract:

In a time of global vaccine shortages, especially for COVID-19 products, Serum Institute of India (SII) is straining to meet demand for vaccines in India. While this organization is not known worldwide, they entered into a recent alliance with AstraZeneca, who is partnered with Oxford University for Covid-19 vaccine, to manufacture their supply of vaccines for distribution in India. Several other such partnerships are also underway. And, SII is considering plans to become a much larger player, not only in India, but globally. This commentary is focused on if, when, where, why, and how global expansion could proceed. Our work was carried out as a class project to identify options and strategies appropriate for expansion and has been expanded subsequently as events continued to develop.